Healthcare Industry News: Baxter International
News Release - June 18, 2009
Calcionics Appoints Daniel O. Wilds Executive ChairmanBELLEVUE, Wash.--(HSMN NewsFeed)--Calcionics Corporation, an emerging biotechnology company developing novel therapies to prevent and treat cardiovascular disease by targeting vascular calcification, or “hardening of the arteries,” today announced the appointment of Daniel O. Wilds as Executive Chairman of the Company’s Board of Directors. Mr. Wilds is a senior healthcare executive with extensive private and public company leadership and board experience.
Mr. Wilds recently retired as CEO of SCOLR Pharma, Inc. He previously served as Chairman and CEO at Northwest Biotherapeutics, Inc., as CEO at Shiloov Biotechnologies (USA), as CEO of Adeza BioMedical, and as CEO of Medisense, Inc. Mr. Wilds started his career at Baxter International in 1968 where he held various domestic and international senior management positions for more than 20 years including being president of Baxter’s chemotherapy service business and of Travenol-Genentech, a joint venture between Baxter and Genentech. He currently serves on the board of directors of Helix BioMedix, Inc.
Charles “Chip” Jacob, co-founder and Chief Executive Officer of Calcionics, said, “We are extremely pleased to have Dan Wilds join Calcionics’ leadership team. His broad base of experience leading research, development, and commercialization will be invaluable as we initiate clinical development and seek appropriate partners for our technology.”
Commenting on his appointment, Mr. Wilds said, “Calcionics represents a unique opportunity to participate in the further development of an exciting new class of cardiovascular therapeutics. I look forward to working with its board and management to achieve its objective of advancing potentially important new treatments for cardiovascular disease."
Based in Bellevue, Washington, Calcionics Corporation is a private company currently raising funds to complete pre-clinical studies and launch clinical trials investigating the safety and utility of its lead product candidate, CALC-100, a bioengineered peptide (fragment) of osteopontin, a naturally occurring anti-calcific protein. Prior animal work in co-founder Dr. Cecilia Giachelli’s laboratory at the University of Washington demonstrated osteopontin’s ability to prevent further calcification and to remove existing calcification from the vasculature and from implanted devices such as bioprosthetic heart valve tissue.
Ectopic calcification, or inappropriate hardening of soft tissue, is present in many cardiovascular conditions including arteriosclerosis (arterial medial calcification), atherosclerosis (intimal calcification), and aortic sclerosis (calcific aortic valve disease). It is estimated that over 90% of atherosclerotic plaques are calcified, and the degree of calcification correlates with adverse events and survival. Calcionics’ novel product candidates are designed to remove calcification and restore pliability to stiffened blood vessels to alleviate hardening of the arteries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.